Business · 27/09/2011Updated: 10/17/2026 · 1 min read
FDA Releases Guidance on User Fee Waivers for Drug and Biological Products
Summary
The Food and Drug Administration (FDA) has made available a new guidance document that provides recommendations for applicants considering user fee waivers, reductions, or refunds for drug and biological products, replacing a previous draft guidance from July 16, 1993.
Original source language: Federal Register — Health and Human ServicesOpen original release →